SEC 13F Intelligence

Managers / Q4 2024 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$150M
Q4 2024
Positions
86
Filings on Record
30
2019–present window
Filed
Feb 14, 2025
original filing

Summary

Sectoral Asset Management Inc reported $150M in U.S.-listed holdings across 86 positions for Q4 2024.

Its largest position, LENZ, represents 18.8% of the portfolio.

Compared with Q3 2024, the fund opened 9 new positions and exited 13.

Portfolio Metrics

Turnover
+9.4%
vs prior filed quarter
Top-10 Concentration
+52.9%
share of reported value
Largest Position
+18.8%
Lenz Therapeutics
New / Exited
9 / 13
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 92.8%ADR: 6.2%ETP: 0.5%Other: 0.5%
  • Common Stock · 92.8% · $139M
  • ADR · 6.2% · $9M
  • ETP · 0.5% · $802,640
  • Other · 0.5% · $782,030

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
HCATHEALTH CATALYST INCNEW+160.0K160.0K+$1M$1M
PRVAPRIVIA HEALTH GROUPNEW+52.0K52.0K+$1M$1M
CLOVCLOVER HEALTH INV CONEW+275.0K275.0K+$866,250$866,250
CITHE CIGNA GROUPNEW+2.3K2.3K+$621,315$621,315
IOVAIOVANCE BIOTHERAPEUTNEW+81.5K81.5K+$603,100$603,100
INCYINCYTE CORPORATIONNEW+2.5K2.5K+$172,675$172,675
CRGXCARGO THERAPEUTICSNEW+8.5K8.5K+$122,570$122,570
AXSMAXSOME THERAPEUTICS INCNEW+820820+$69,380$69,380

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

86 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LENZLENZ THERAPEUTICShistory →COM18.83%$28M977.2K
2CTNMCONTINEUM THERAPEUTIhistory →CL A7.83%$12M800.8K
3LLYELI LILLY & COhistory →COM6.46%$10M12.5K
4UNHUNITEDHEALTH GRP INChistory →COM4.94%$7M14.6K
5GILDGILEAD SCIENCES INChistory →COM3.16%$5M51.3K
6MLYSMINERALYS THERAPEUTIhistory →COM3.13%$5M380.9K
7ABBVABBVIE INChistory →COM2.23%$3M18.8K
8JNJJOHNSON & JOHNSONhistory →COM2.21%$3M22.9K
9AMGNAMGEN INChistory →COM2.18%$3M12.6K
10BSXBOSTON SCIENTIFIChistory →COM1.94%$3M32.5K
11ABTABBOTT LABShistory →COM1.84%$3M24.4K
12BMYBRISTOL MYERS SQUIBBhistory →COM1.66%$2M44.0K
13TMOTHERMO FISHER SCIhistory →COM1.65%$2M4.8K
14MRKMERCK & CO INChistory →COM1.63%$2M24.5K
15REGNREGENERON PHARMCTCLShistory →COM1.62%$2M3.4K
16SYKSTRYKER CORPhistory →COM1.54%$2M6.4K
17BNTXBIONTECH SEhistory →SPN ADS1.44%$2M18.9K
18MDTMEDTRONIC PLChistory →SHS1.41%$2M26.4K
19ARGXARGENX SEhistory →SPN ADR1.41%$2M3.4K
20PFEPFIZER INChistory →COM1.37%$2M77.7K
21BOLDBOUNDLESS BIO INChistory →COM1.31%$2M678.6K
22ALNYALNYLAM PHARMACUETCLhistory →COM1.30%$2M8.3K
23BMRNBIOMARIN PHARMAC INChistory →COM1.29%$2M29.4K
24DHRDANAHER CORPhistory →COM1.12%$2M7.3K
25NBIXNEUROCRINE BIOSCIENChistory →COM1.08%$2M11.8K
26ISRGINTUITIVE SURGIC INChistory →COM NEW1.06%$2M3.0K
27PCVXVAXCYTE INChistory →COM1.04%$2M18.9K
28VRTXVERTEX PHARMACOM0.99%$1M3.7K
29SRPTSAREPTA THERAPEUTICSCOM0.89%$1M11.0K
30GPCRSTRUCTURE THERAPEUSPN ADS0.89%$1M49.3K
31MLTXMOONLAKE IMMUNOTHERACLASS A ORD0.86%$1M23.7K
32AMICUS THERAPEUTICS INCCOM0.85%$1M135.6K
33QUREUNIQURE N.V.SHS0.84%$1M71.5K
34ZLABZAI LAB LTDADR0.78%$1M44.8K
35CYTKCYTOKINETICS INCCOM NEW0.77%$1M24.5K
36HCATHEALTH CATALYST INCCOM0.76%$1M160.0K
37TARSTARSUS PHARMACEUTICACOM0.75%$1M20.3K
38SPRYARS PHARMACEUTICALS INCCOM0.75%$1M106.0K
39BLUEPRINT MEDICINESCOM0.73%$1M12.6K
40RCUSARCUS BIOSCIENCES INCCOM0.69%$1M69.6K
41PRVAPRIVIA HEALTH GROUPCOM0.68%$1M52.0K
42CVSCVS HEALTH CORPCOM0.66%$987,58022.0K
43LEGNLEGEND BIOTECH CORPSPN ADS0.65%$969,69229.8K
44AZNNASTRAZENECA PLCSPN ADR0.64%$959,86814.7K
45CLOVCLOVER HEALTH INV COCOM CL A0.58%$866,250275.0K
46SGOVISHARES TR0-3 MNTH TREASRY0.54%$802,6408.0K
47INARI MED INCCOM0.52%$773,56115.2K
48CITHE CIGNA GROUPCOM0.41%$621,3152.3K
49IOVAIOVANCE BIOTHERAPEUTCOM0.40%$603,10081.5K
50BIIBBIOGEN INCCOM0.39%$589,0483.9K
51ILMNILLUMINA INCCOM0.39%$583,9634.4K
52EWEDWARDS LIFESCIENCECOM0.39%$581,1367.8K
53ARVNARVINAS INCCOM0.39%$577,97630.1K
54COGTCOGENT BIOSCIENCESCOM0.38%$575,64073.8K
55SMMTSUMMIT THERAPEUTICSCOM0.36%$535,35030.0K
56ENGENE HOLDINGS INCCOM0.35%$524,81178.9K
57INSMINSMED INCCOM0.34%$508,8947.4K
58RCKTROCKET PHARMACEUTICACOM0.34%$505,10040.2K
59INTRA CELLULAR THERACOM0.27%$409,2484.9K
60ROIVROIVANT SCIENCES LTDSHS0.27%$408,13534.5K
61HUMHUMANA INCCOM0.27%$401,1161.6K
62ONCBEIGENE LTDSPN ADR0.25%$371,2672.0K
63OLMAOLEMA PHARMACEUTICALCOM0.24%$359,42061.6K
64BBIOBRIDGEBIO PHARMA INCCOM0.21%$315,56011.5K
65MEDPMEDPACE HOLDINGSCOM0.18%$275,751830
66PTCTPTC THERAPEUTICSCOM0.17%$261,8125.8K
67TURNSTONE BIOLOGICSCOM0.17%$257,219517.6K
68IONSIONIS PHARMACEUTICALCOM0.17%$251,7127.2K
69VERAVERA THERAPEUTICSCL A0.16%$241,0535.7K
70CRNXCRINETICS PHARMACECOM0.15%$224,9724.4K
71GERNGERON CORPCOM0.15%$224,79063.5K
72ASNDASCENDIS PHARMA ASSPN ADR0.15%$220,2721.6K
73JAZZJAZZ PHARMA PLCSHS USD0.14%$215,5131.8K
74RVMDREVOLUTION MEDICINCOM0.14%$214,3264.9K
75UTHRUNITED THERAPEUTICSCOM0.14%$209,940595
76SPRINGWORKS THERAPEUCOM0.13%$198,7155.5K
77VTRSVIATRIS INCCOM0.13%$194,22015.6K
78NVONOVO-NORDISK ASADR0.13%$189,2442.2K
79RPRXROYALTY PHARMA PLCSHS CLASS A0.12%$183,6727.2K
80MRNAMODERNA INCCOM0.12%$180,8734.3K
81MDGLMADRIGAL PHARMACEUTICOM0.12%$175,885570
82INCYINCYTE CORPORATIONCOM0.12%$172,6752.5K
83CRGXCARGO THERAPEUTICSCOM0.08%$122,5708.5K
84EXELEXELIXIS INCCOM0.08%$116,5503.5K
85AXSMAXSOME THERAPEUTICS INCCOM0.05%$69,380820
86IOBTQIO BIOTECH INCCOM0.05%$69,00075.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.